Novel chalcone analogs were designed and synthesized as human MAO-B reversible inhibitors.
The inhibitors bind with micromolar to submicromolar potency.
The molecular scaffold determines high MAO-A/MAO-B selectivity.
A double conformation in MAO-B active site is predicted by molecular docking.